{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:21:49Z","timestamp":1791876109294,"version":"4.3.4"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1038\/s41585-022-00680-4","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T13:35:15Z","timestamp":1672839315000},"page":"205-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Prostate cancer risk, screening and management in patients with germline BRCA1\/2 mutations"],"prefix":"10.1038","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4073-6584","authenticated-orcid":false,"given":"Pawel","family":"Rajwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad","family":"Quhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7768-8558","authenticated-orcid":false,"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-2152","authenticated-orcid":false,"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Leapman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Paradysz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1140-0603","authenticated-orcid":false,"given":"Todd M.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh S.","family":"Palapattu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6627-6179","authenticated-orcid":false,"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"680_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euo.2020.11.011","volume":"4","author":"S Loeb","year":"2021","unstructured":"Loeb, S. & Giri, V. N. Clinical implications of germline testing in newly diagnosed prostate cancer. Eur. Urol. Oncol. 4, 1\u20139 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"680_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1002\/pros.23795","volume":"79","author":"M Oh","year":"2019","unstructured":"Oh, M. et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis. Prostate 79, 880\u2013895 (2019).","journal-title":"Prostate"},{"key":"680_CR3","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"CC Pritchard","year":"2016","unstructured":"Pritchard, C. C. et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375, 443\u2013453 (2016).","journal-title":"N. Engl. J. Med."},{"key":"680_CR4","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1097\/JU.0000000000001570","volume":"205","author":"N Shore","year":"2021","unstructured":"Shore, N. et al. Systematic literature review of the epidemiology of advanced prostate cancer and associated homologous recombination repair gene alterations. J. Urol. 205, 977\u2013986 (2021).","journal-title":"J. Urol."},{"key":"680_CR5","doi-asserted-by":"publisher","first-page":"5864","DOI":"10.1038\/sj.onc.1209874","volume":"25","author":"K Gudmundsdottir","year":"2006","unstructured":"Gudmundsdottir, K. & Ashworth, A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864\u20135874 (2006).","journal-title":"Oncogene"},{"key":"680_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41585-022-00580-7","volume":"19","author":"J Russo","year":"2022","unstructured":"Russo, J. & Giri, V. N. Germline testing and genetic counselling in prostate cancer. Nat. Rev. Urol. 19, 331\u2013343 (2022).","journal-title":"Nat. Rev. Urol."},{"key":"680_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0691-1","volume":"12","author":"NS Abul-Husn","year":"2019","unstructured":"Abul-Husn, N. S. et al. Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based biobank. Genome Med. 12, 2 (2019).","journal-title":"Genome Med."},{"key":"680_CR8","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","volume":"373","author":"J Mateo","year":"2015","unstructured":"Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697\u20131708 (2015).","journal-title":"N. Engl. J. Med."},{"key":"680_CR9","first-page":"00039","volume":"16","author":"VN Giri","year":"2017","unstructured":"Giri, V. N. et al. Inherited mutations in men undergoing multigene panel testing for prostate cancer: emerging implications for personalized prostate cancer genetic evaluation. JCO Precis. Oncol. 16, 00039 (2017).","journal-title":"JCO Precis. Oncol."},{"key":"680_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","volume":"5","author":"P Nicolosi","year":"2019","unstructured":"Nicolosi, P. et al. Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines. JAMA Oncol. 5, 523\u2013528 (2019).","journal-title":"JAMA Oncol."},{"key":"680_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/pros.23484","volume":"78","author":"P Isaacsson Velho","year":"2018","unstructured":"Isaacsson Velho, P. et al. Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate 78, 401\u2013407 (2018).","journal-title":"Prostate"},{"key":"680_CR12","doi-asserted-by":"publisher","first-page":"3740","DOI":"10.1200\/JCO.20.01755","volume":"38","author":"MT Schweizer","year":"2020","unstructured":"Schweizer, M. T., Cheng, H. H., Nelson, P. S. & Montgomery, R. B. Two steps forward and one step back for precision in prostate cancer treatment. J. Clin. Oncol. 38, 3740\u20133742 (2020).","journal-title":"J. Clin. Oncol."},{"key":"680_CR13","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer Early Detection (version 1.2022). NCCN https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate_detection.pdf (2022)."},{"key":"680_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","volume":"79","author":"N Mottet","year":"2021","unstructured":"Mottet, N. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur. Urol. 79, 243\u2013262 (2021).","journal-title":"Eur. Urol."},{"key":"680_CR15","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","volume":"64","author":"S Loeb","year":"2013","unstructured":"Loeb, S. et al. Systematic review of complications of prostate biopsy. Eur. Urol. 64, 876\u2013892 (2013).","journal-title":"Eur. Urol."},{"key":"680_CR16","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.2018.3712","volume":"319","author":"JJ Fenton","year":"2018","unstructured":"Fenton, J. J. et al. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA 319, 1914\u20131931 (2018).","journal-title":"JAMA"},{"key":"680_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.eururo.2020.12.039","volume":"79","author":"AS Merseburger","year":"2021","unstructured":"Merseburger, A. S. et al. Genomic testing in patients with metastatic castration-resistant prostate cancer: a pragmatic guide for clinicians. Eur. Urol. 79, 519\u2013529 (2021).","journal-title":"Eur. Urol."},{"key":"680_CR18","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.annonc.2020.06.025","volume":"31","author":"N Segal","year":"2020","unstructured":"Segal, N. et al. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening. Ann. Oncol. 31, 1545\u20131552 (2020).","journal-title":"Ann. Oncol."},{"key":"680_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.eururo.2019.08.025","volume":"77","author":"T Nyberg","year":"2020","unstructured":"Nyberg, T. et al. Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Eur. Urol. 77, 24\u201335 (2020).","journal-title":"Eur. Urol."},{"key":"680_CR20","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.eururo.2019.08.019","volume":"76","author":"EC Page","year":"2019","unstructured":"Page, E. C. et al. Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers. Eur. Urol. 76, 831\u2013842 (2019).","journal-title":"Eur. Urol."},{"key":"680_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/s41416-021-01675-5","volume":"126","author":"T Nyberg","year":"2021","unstructured":"Nyberg, T., Tischkowitz, M. & Antoniou, A. C. BRCA1 and BRCA2 pathogenic variants and prostate cancer risk: systematic review and meta-analysis. Br. J. Cancer 126, 1067\u20131081 (2021).","journal-title":"Br. J. Cancer"},{"key":"680_CR22","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMms1914228","volume":"382","author":"HG Welch","year":"2020","unstructured":"Welch, H. G. & Albertsen, P. C. Reconsidering prostate cancer mortality - the future of PSA screening. N. Engl. J. Med. 382, 1557\u20131563 (2020).","journal-title":"N. Engl. J. Med."},{"key":"680_CR23","doi-asserted-by":"publisher","first-page":"EVIDoa2200031","DOI":"10.1056\/EVIDoa2200031","volume":"1","author":"SP Basourakos","year":"2022","unstructured":"Basourakos, S. P. et al. Harm-to-benefit of three decades of prostate cancer screening in Black men. NEJM Evid. 1, EVIDoa2200031 (2022).","journal-title":"NEJM Evid."},{"key":"680_CR24","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schr\u00f6der","year":"2014","unstructured":"Schr\u00f6der, F. H. et al. Screening and prostate cancer mortality: results of the European randomised study of screening for prostate cancer (ERSPC) at 13 years of follow-up. Lancet 384, 2027\u20132035 (2014).","journal-title":"Lancet"},{"key":"680_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson, J. et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur. Urol. 76, 43\u201351 (2019).","journal-title":"Eur. Urol."},{"key":"680_CR26","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.eururo.2012.05.068","volume":"62","author":"FH Schroder","year":"2012","unstructured":"Schroder, F. H. et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European randomized study of screening for prostate cancer (ERSPC). Eur. Urol. 62, 745\u2013752 (2012).","journal-title":"Eur. Urol."},{"key":"680_CR27","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/bju.14580","volume":"123","author":"PF Pinsky","year":"2019","unstructured":"Pinsky, P. F. et al. Extended follow-up for prostate cancer incidence and mortality among participants in the prostate, lung, colorectal and ovarian randomized cancer screening trial. BJU Int. 123, 854\u2013860 (2019).","journal-title":"BJU Int."},{"key":"680_CR28","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/cncr.30474","volume":"123","author":"PF Pinsky","year":"2017","unstructured":"Pinsky, P. F. et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 123, 592\u2013599 (2017).","journal-title":"Cancer"},{"key":"680_CR29","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1056\/NEJMoa0810696","volume":"360","author":"GL Andriole","year":"2009","unstructured":"Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310\u20131319 (2009).","journal-title":"N. Engl. J. Med."},{"key":"680_CR30","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.2018.0154","volume":"319","author":"RM Martin","year":"2018","unstructured":"Martin, R. M. et al. Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA 319, 883\u2013895 (2018).","journal-title":"JAMA"},{"key":"680_CR31","unstructured":"Howlader N, et al. (eds). SEER Cancer Statistics Review, 1975\u20132017. National Cancer Institute https:\/\/seer.cancer.gov\/csr\/1975_2017\/ (2020)."},{"key":"680_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.euf.2017.10.014","volume":"4","author":"SP Kelly","year":"2018","unstructured":"Kelly, S. P., Anderson, W. F., Rosenberg, P. S. & Cook, M. B. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur. Urol. Focus. 4, 121\u2013127 (2018).","journal-title":"Eur. Urol. Focus."},{"key":"680_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/jamaoncol.2021.5143","volume":"8","author":"MS Leapman","year":"2022","unstructured":"Leapman, M. S. et al. Changes in prostate-specific antigen testing relative to the revised US preventive services task force recommendation on prostate cancer screening. JAMA Oncol. 8, 41\u201347 (2022).","journal-title":"JAMA Oncol."},{"key":"680_CR34","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","volume":"80","author":"H Van Poppel","year":"2021","unstructured":"Van Poppel, H. et al. Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021. Eur. Urol. 80, 703\u2013711 (2021).","journal-title":"Eur. Urol."},{"key":"680_CR35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.eururo.2019.10.030","volume":"77","author":"DE Neal","year":"2020","unstructured":"Neal, D. E. et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protect randomised controlled trial according to treatment received. Eur. Urol. 77, 320\u2013330 (2020).","journal-title":"Eur. Urol."},{"key":"680_CR36","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","volume":"375","author":"FC Hamdy","year":"2016","unstructured":"Hamdy, F. C. et al. 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415\u20131424 (2016).","journal-title":"N. Engl. J. Med."},{"key":"680_CR37","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa1615869","volume":"377","author":"TJ Wilt","year":"2017","unstructured":"Wilt, T. J. et al. Follow-up of prostatectomy versus observation for early prostate cancer. N. Engl. J. Med. 377, 132\u2013142 (2017).","journal-title":"N. Engl. J. Med."},{"key":"680_CR38","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1200\/JCO.2010.31.2330","volume":"29","author":"PC Albertsen","year":"2011","unstructured":"Albertsen, P. C. et al. Impact of comorbidity on survival among men with localized prostate cancer. J. Clin. Oncol. 29, 1335\u20131341 (2011).","journal-title":"J. Clin. Oncol."},{"key":"680_CR39","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.eururo.2018.09.034","volume":"75","author":"M Moschini","year":"2019","unstructured":"Moschini, M. et al. External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: a population-based analysis. Eur. Urol. 75, 319\u2013328 (2019).","journal-title":"Eur. Urol."},{"key":"680_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41391-017-0028-3","volume":"21","author":"MA Awad","year":"2018","unstructured":"Awad, M. A. et al. Prostate cancer radiation and urethral strictures: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 21, 168\u2013174 (2018).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"680_CR41","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/jnci\/djp278","volume":"101","author":"HG Welch","year":"2009","unstructured":"Welch, H. G. & Albertsen, P. C. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986\u20132005. J. Natl Cancer Inst. 101, 1325\u20131329 (2009).","journal-title":"J. Natl Cancer Inst."},{"key":"680_CR42","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.euo.2022.04.006","volume":"5","author":"T Kawada","year":"2022","unstructured":"Kawada, T. et al. Diagnostic performance of prostate-specific membrane antigen positron emission tomography-targeted biopsy for detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur. Urol. Oncol. 5, 390\u2013400 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"680_CR43","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2022.03.031","volume":"82","author":"P Rajwa","year":"2022","unstructured":"Rajwa, P. et al. Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer: a systematic review and meta-analysis. Eur. Urol. 82, 82\u201396 (2022).","journal-title":"Eur. Urol."},{"key":"680_CR44","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.eururo.2019.09.004","volume":"77","author":"NJ Sathianathen","year":"2020","unstructured":"Sathianathen, N. J. et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. Eur. Urol. 77, 365\u2013372 (2020).","journal-title":"Eur. Urol."},{"key":"680_CR45","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 36, 446\u2013453 (2018).","journal-title":"J. Clin. Oncol."},{"key":"680_CR46","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan, V. et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis. N. Engl. J. Med. 378, 1767\u20131777 (2018).","journal-title":"N. Engl. J. Med."},{"key":"680_CR47","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa2100852","volume":"385","author":"M Eklund","year":"2021","unstructured":"Eklund, M. et al. MRI-targeted or standard biopsy in prostate cancer screening. N. Engl. J. Med. 385, 908\u2013920 (2021).","journal-title":"N. Engl. J. Med."},{"key":"680_CR48","doi-asserted-by":"publisher","first-page":"100212","DOI":"10.1016\/j.ctarc.2020.100212","volume":"25","author":"S Loeb","year":"2020","unstructured":"Loeb, S. et al. Knowledge and practice regarding prostate cancer germline testing among urologists: gaps to address for optimal implementation. Cancer Treat. Res. Commun. 25, 100212 (2020).","journal-title":"Cancer Treat. Res. Commun."},{"key":"680_CR49","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/pros.24172","volume":"81","author":"S Loeb","year":"2021","unstructured":"Loeb, S. et al. Barriers and facilitators of germline genetic evaluation for prostate cancer. Prostate 81, 754\u2013764 (2021).","journal-title":"Prostate"},{"key":"680_CR50","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (version 1.2023). NCCN https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf (2022)."},{"key":"680_CR51","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jamaoncol.2020.2059","volume":"6","author":"T Hadar","year":"2020","unstructured":"Hadar, T. et al. Presymptomatic awareness of germline pathogenic BRCA variants and associated outcomes in women with breast cancer. JAMA Oncol. 6, 1460\u20131463 (2020).","journal-title":"JAMA Oncol."},{"key":"680_CR52","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer (version 1.2023). NCCN https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (2022)."},{"key":"680_CR53","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/JCO.20.00046","volume":"38","author":"VN Giri","year":"2020","unstructured":"Giri, V. N. et al. Implementation of germline testing for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J. Clin. Oncol. 38, 2798\u20132811 (2020).","journal-title":"J. Clin. Oncol."},{"key":"680_CR54","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/JCO.2012.43.1882","volume":"31","author":"E Castro","year":"2013","unstructured":"Castro, E. et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol. 31, 1748\u20131757 (2013).","journal-title":"J. Clin. Oncol."},{"key":"680_CR55","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1002\/cncr.32908","volume":"126","author":"MA Dall\u2019Era","year":"2020","unstructured":"Dall\u2019Era, M. A. et al. Germline and somatic DNA repair gene alterations in prostate cancer. Cancer 126, 2980\u20132985 (2020).","journal-title":"Cancer"},{"key":"680_CR56","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","volume":"71","author":"R Na","year":"2017","unstructured":"Na, R. et al. Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur. Urol. 71, 740\u2013747 (2017).","journal-title":"Eur. Urol."},{"key":"680_CR57","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"A Abeshouse","year":"2015","unstructured":"Abeshouse, A. et al. The molecular taxonomy of primary prostate cancer. Cell 163, 1011\u20131025 (2015).","journal-title":"Cell"},{"key":"680_CR58","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.eururo.2021.03.031","volume":"80","author":"JE Berchuck","year":"2021","unstructured":"Berchuck, J. E. et al. Impact of pathogenic germline DNA damage repair alterations on response to intense neoadjuvant androgen deprivation therapy in high-risk localized prostate cancer. Eur. Urol. 80, 295\u2013303 (2021).","journal-title":"Eur. Urol."},{"key":"680_CR59","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","volume":"8","author":"Y Momozawa","year":"2022","unstructured":"Momozawa, Y. et al. Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants. JAMA Oncol. 8, 871\u2013878 (2022).","journal-title":"JAMA Oncol."},{"key":"680_CR60","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1200\/JCO.21.02112","volume":"40","author":"S Li","year":"2022","unstructured":"Li, S. et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J. Clin. Oncol. 40, 1529\u20131541 (2022).","journal-title":"J. Clin. Oncol."},{"key":"680_CR61","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10549-015-3340-4","volume":"150","author":"Y Laitman","year":"2015","unstructured":"Laitman, Y. et al. Cancer risks in Jewish male BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 150, 631\u2013635 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"680_CR62","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/cncr.29041","volume":"121","author":"J Mersch","year":"2015","unstructured":"Mersch, J. et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 121, 269\u2013275 (2015).","journal-title":"Cancer"},{"key":"680_CR63","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2018.0271","volume":"4","author":"R Mano","year":"2018","unstructured":"Mano, R. et al. Malignant abnormalities in male BRCA mutation carriers: results from a prospectively screened cohort. JAMA Oncol. 4, 872\u2013874 (2018).","journal-title":"JAMA Oncol."},{"key":"680_CR64","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.eururo.2014.01.003","volume":"66","author":"EK Bancroft","year":"2014","unstructured":"Bancroft, E. K. et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur. Urol. 66, 489\u2013499 (2014).","journal-title":"Eur. Urol."},{"key":"680_CR65","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.juro.2016.10.099","volume":"197","author":"DF Gleason","year":"2017","unstructured":"Gleason, D. F. & Mellinger, G. T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J. Urol. 197, S134\u2013S139 (2017).","journal-title":"J. Urol."},{"key":"680_CR66","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","volume":"40","author":"JI Epstein","year":"2016","unstructured":"Epstein, J. I. et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am. J. Surgical Pathol. 40, 244\u2013252 (2016).","journal-title":"Am. J. Surgical Pathol."},{"key":"680_CR67","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1200\/JCO.1999.17.1.168","volume":"17","author":"AV D\u2019Amico","year":"1999","unstructured":"D\u2019Amico, A. V. et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J. Clin. Oncol. 17, 168\u2013168 (1999).","journal-title":"J. Clin. Oncol."},{"key":"680_CR68","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1002\/cncr.26169","volume":"117","author":"MR Cooperberg","year":"2011","unstructured":"Cooperberg, M. R., Hilton, J. F. & Carroll, P. R. The CAPRA-S score. Cancer 117, 5039\u20135046 (2011).","journal-title":"Cancer"},{"key":"680_CR69","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1111\/j.1464-410X.2012.11481.x","volume":"110","author":"LP Bokhorst","year":"2012","unstructured":"Bokhorst, L. P. et al. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial. BJU Int. 110, 1654\u20131660 (2012).","journal-title":"BJU Int."},{"key":"680_CR70","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/bju.12368","volume":"113","author":"PF Pinsky","year":"2014","unstructured":"Pinsky, P. F., Parnes, H. L. & Andriole, G. Mortality and complications after prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening (PLCO) trial. BJU Int. 113, 254\u2013259 (2014).","journal-title":"BJU Int."},{"key":"680_CR71","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamaoncol.2020.7456","volume":"7","author":"D Eldred-Evans","year":"2021","unstructured":"Eldred-Evans, D. et al. Population-based prostate cancer screening with magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study. JAMA Oncol. 7, 395\u2013402 (2021).","journal-title":"JAMA Oncol."},{"key":"680_CR72","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euo.2020.12.004","volume":"4","author":"E Mazzone","year":"2021","unstructured":"Mazzone, E. et al. Positive predictive value of prostate imaging reporting and data system version 2 for the detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur. Urol. Oncol. 4, 697\u2013713 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"680_CR73","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1097\/JU.0000000000001306","volume":"204","author":"KJ Park","year":"2020","unstructured":"Park, K. J. et al. Risk stratification of prostate cancer according to PI-RADS(R) version 2 categories: meta-analysis for prospective studies. J. Urol. 204, 1141\u20131149 (2020).","journal-title":"J. Urol."},{"key":"680_CR74","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.eururo.2018.08.038","volume":"74","author":"B Van Calster","year":"2018","unstructured":"Van Calster, B. et al. Reporting and interpreting decision curve analysis: a guide for investigators. Eur. Urol. 74, 796\u2013804 (2018).","journal-title":"Eur. Urol."},{"key":"680_CR75","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S1470-2045(21)00348-X","volume":"22","author":"T Nordstr\u00f6m","year":"2021","unstructured":"Nordstr\u00f6m, T. et al. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial. Lancet Oncol. 22, 1240\u20131249 (2021).","journal-title":"Lancet Oncol."},{"key":"680_CR76","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.euo.2021.06.004","volume":"4","author":"A Boil\u00e8ve","year":"2021","unstructured":"Boil\u00e8ve, A., Lavaud, P. & Caron, O. Germline BRCA1 mutation and prostate cancer: be careful on causality. Eur. Urol. Oncol. 4, 674\u2013675 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"680_CR77","doi-asserted-by":"publisher","first-page":"4986365","DOI":"10.1155\/2020\/4986365","volume":"2020","author":"C Messina","year":"2020","unstructured":"Messina, C. et al. BRCA mutations in prostate cancer: prognostic and predictive implications. J. Oncol. 2020, 4986365 (2020).","journal-title":"J. Oncol."},{"key":"680_CR78","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41585-019-0164-8","volume":"16","author":"RA Taylor","year":"2019","unstructured":"Taylor, R. A. et al. The influence of BRCA2 mutation on localized prostate cancer. Nat. Rev. Urol. 16, 281\u2013290 (2019).","journal-title":"Nat. Rev. Urol."},{"key":"680_CR79","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","volume":"75","author":"HB Carter","year":"2019","unstructured":"Carter, H. B. et al. Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer. Eur. Urol. 75, 743\u2013749 (2019).","journal-title":"Eur. Urol."},{"issue":"Suppl. 7","key":"680_CR80","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JCO.2019.37.7_suppl.19","volume":"37","author":"M Dall\u2019era","year":"2019","unstructured":"Dall\u2019era, M. et al. Are prostate cancer patients with BRCA1 and BRCA2 mutations safe for active surveillance? J. Clin. Oncol. 37 (Suppl. 7), 19 (2019).","journal-title":"J. Clin. Oncol."},{"key":"680_CR81","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","volume":"80","author":"P Rajwa","year":"2021","unstructured":"Rajwa, P. et al. Reliability of serial prostate magnetic resonance imaging to detect prostate cancer progression during active surveillance: a systematic review and meta-analysis. Eur. Urol. 80, 549\u2013563 (2021).","journal-title":"Eur. Urol."},{"key":"680_CR82","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.3187","volume":"6","author":"MR Cooperberg","year":"2020","unstructured":"Cooperberg, M. R. et al. Tailoring intensity of active surveillance for low-risk prostate cancer based on individualized prediction of risk stability. JAMA Oncol. 6, e203187 (2020).","journal-title":"JAMA Oncol."},{"key":"680_CR83","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1097\/JU.0000000000001701","volume":"205","author":"P Rajwa","year":"2021","unstructured":"Rajwa, P. et al. Association of negative followup biopsy and reclassification during active surveillance of prostate cancer: a systematic review and meta-analysis. J. Urol. 205, 1559\u20131568 (2021).","journal-title":"J. Urol."},{"key":"680_CR84","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/JU.0000000000001027","volume":"204","author":"D Halstuch","year":"2020","unstructured":"Halstuch, D. et al. Short-term outcomes of active surveillance for low risk prostate cancer among men with germline DNA repair gene mutations. J. Urol. 204, 707\u2013713 (2020).","journal-title":"J. Urol."},{"key":"680_CR85","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.euf.2019.05.009","volume":"6","author":"D Halstuch","year":"2020","unstructured":"Halstuch, D., Ber, Y. & Margel, D. Screening, active surveillance, and treatment of localized prostate cancer among carriers of germline BRCA mutations. Eur. Urol. Focus. 6, 212\u2013214 (2020).","journal-title":"Eur. Urol. Focus."},{"key":"680_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0004812","volume":"4","author":"PL Mai","year":"2009","unstructured":"Mai, P. L. et al. Potential excess mortality in BRCA1\/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers and melanoma. PLoS ONE 4, e4812 (2009).","journal-title":"PLoS ONE"},{"key":"680_CR87","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S1470-2045(21)00571-4","volume":"22","author":"G Gandaglia","year":"2021","unstructured":"Gandaglia, G., Briganti, A. & Montorsi, F. Reimagining prostate cancer screening: the IMPACT of germline mutations. Lancet Oncol. 22, 1491\u20131492 (2021).","journal-title":"Lancet Oncol."},{"key":"680_CR88","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","volume":"68","author":"E Castro","year":"2015","unstructured":"Castro, E. et al. Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer. Eur. Urol. 68, 186\u2013193 (2015).","journal-title":"Eur. Urol."},{"key":"680_CR89","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.euf.2021.04.018","volume":"7","author":"R Clark","year":"2021","unstructured":"Clark, R., McAlpine, K. & Fleshner, N. A clinical trial of prophylactic prostatectomy for BRCA2 mutation carriers: is now the time? Eur. Urol. Focus. 7, 506\u2013507 (2021).","journal-title":"Eur. Urol. Focus."},{"key":"680_CR90","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"M Hussain","year":"2020","unstructured":"Hussain, M. et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N. Engl. J. Med. 383, 2345\u20132357 (2020).","journal-title":"N. Engl. J. Med."},{"key":"680_CR91","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.euo.2020.07.005","volume":"3","author":"ES Antonarakis","year":"2020","unstructured":"Antonarakis, E. S., Gomella, L. G. & Petrylak, D. P. When and how to use PARP inhibitors in prostate cancer: a systematic review of the literature with an update on on-going trials. Eur. Urol. Oncol. 3, 594\u2013611 (2020).","journal-title":"Eur. Urol. Oncol."},{"key":"680_CR92","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J De Bono","year":"2020","unstructured":"De Bono, J. et al. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382, 2091\u20132102 (2020).","journal-title":"N. Engl. J. Med."},{"key":"680_CR93","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"W Abida","year":"2020","unstructured":"Abida, W. et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol. 38, 3763\u20133772 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"Suppl. 6","key":"680_CR94","doi-asserted-by":"publisher","first-page":"TPS389","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS389","volume":"36","author":"CJ Ryan","year":"2018","unstructured":"Ryan, C. J. et al. TRITON3: an international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician\u2019s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). J. Clin. Oncol. 36 (Suppl. 6), TPS389 (2018).","journal-title":"J. Clin. Oncol."},{"key":"680_CR95","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","volume":"23","author":"MR Smith","year":"2022","unstructured":"Smith, M. R. et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. Lancet Oncol. 23, 362\u2013373 (2022).","journal-title":"Lancet Oncol."},{"key":"680_CR96","doi-asserted-by":"publisher","first-page":"EVIDoa2200043","DOI":"10.1056\/EVIDoa2200043","volume":"1","author":"NW Clarke","year":"2022","unstructured":"Clarke, N. W. et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 1, EVIDoa2200043 (2022).","journal-title":"NEJM Evid."},{"key":"680_CR97","unstructured":"Clovis Oncology. TRITON3 phase 3 trial of Rubraca\u00ae (rucaparib) achieves primary endpoint in men with metastatic castration-resistant prostate cancer with BRCA or ATM mutations. Clovis Oncology https:\/\/ir.clovisoncology.com\/investors-and-news\/news-releases\/press-release-details\/2022\/TRITON3-Phase-3-Trial-of-Rubraca-rucaparib-Achieves-Primary-Endpoint-in-Men-with-Metastatic-Castration-Resistant-Prostate-Cancer-with-BRCA-or-ATM-Mutations\/default.aspx (2022)."},{"key":"680_CR98","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-021-01061-x","volume":"14","author":"D Teyssonneau","year":"2021","unstructured":"Teyssonneau, D. et al. Prostate cancer and PARP inhibitors: progress and challenges. J. Hematol. Oncol. 14, 51 (2021).","journal-title":"J. Hematol. Oncol."},{"key":"680_CR99","doi-asserted-by":"publisher","first-page":"S546","DOI":"10.1016\/j.annonc.2020.08.2083","volume":"31","author":"Z Zumsteg","year":"2020","unstructured":"Zumsteg, Z. et al. 689TiP NRG Oncology\u2019s GU007 (NADIR): a randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I). Ann. Oncol. 31, S546 (2020).","journal-title":"Ann. Oncol."},{"issue":"Suppl. 6","key":"680_CR100","doi-asserted-by":"publisher","first-page":"TPS176","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS176","volume":"39","author":"DE Rathkopf","year":"2021","unstructured":"Rathkopf, D. E. et al. AMPLITUDE: a study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). J. Clin. Oncol. 39 (Suppl. 6), TPS176 (2021).","journal-title":"J. Clin. Oncol."},{"key":"680_CR101","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1200\/JCO.2019.37.15_suppl.5045","volume":"37","author":"ES Antonarakis","year":"2019","unstructured":"Antonarakis, E. S. et al. Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis. J. Clin. Oncol. 37, 5045\u20135045 (2019).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-022-00680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-022-00680-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-022-00680-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T13:09:53Z","timestamp":1680613793000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-022-00680-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":101,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["680"],"URL":"https:\/\/doi.org\/10.1038\/s41585-022-00680-4","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"3 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}